Tag: SpinalCyte

New international patent for SpinalCyte

It was announced at the JPMorgan Healthcare Conference (7–10 January, San Francisco, USA) that SpinalCyte has been issued a new Australian patent related to its...

FDA clears SpinalCyte IND application for universal donor cell therapy to...

The FDA has cleared SpinalCyte’s Investigational New Drug (IND) protocol for CybroCell. This is considered to be the first IND approval for a fibroblast...
SpinalCyte logo

SpinalCyte announces sustained 12-month MRI outcomes after CybroCell injection

SpinalCyte has announced that a single injection of modified human dermal fibroblasts (HDFs) resulted in significant improvements of disc height and pain reduction 12...
SpinalCyte logo

SpinalCyte announces new patents in Hong Kong and Europe

SpinalCyte, a regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), has announced the issuance of new patents...

SpinalCyte announces MRI evidence of disc regeneration following phase 1/phase 2...

MRI analysis of patients who received intradiscal injections of human dermal fibroblasts shows significant improvement in disc height after six months, the latest evidence...
SpinalCyte logo

SpinalCyte granted new Australian patent

SpinalCyte, a tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, has announced today the issuance of...

SpinalCyte granted new Japanese patent

SpinalCyte, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, has been issued a new...

SpinalCyte receives new European patent

SpinalCyte has received European Patent No. 1989289, “Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.” The technology described in the patent...

SpinalCyte enrols first patient in human dermal fibroblasts phase I human...

SpinalCyte, an engineering technology company focused on the regrowth of the spinal disc nucleus using human dermal fibroblasts, has announced the enrolment of its...

SpinalCyte receives new US patent

SpinalCyte has received US patent number 9,533,024, “Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.” The technology described in the patent...

SpinalCyte receives Institutional Review Board approval for phase I clinical trial

SpinalCyte has received Institutional Review Board approval to begin clinical trials with its dermal fibroblast cell product, CybroCell, in the treatment of degenerative disc...